This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
N-Gene Research and Development, Ltd.
Drug Names(s): R,S-O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid
Description: BGP-15 is an inhibitor of Poly (ADP-ribose)-polymerase (PARP).
Deal Structure: In March 2002, Allos Therapeutics entered into an in-licensing agreement with N-Gene, under which it obtained an exclusive United States license to BGP-15, which it planned to develop as a chemotherapy sensitizer. On October 9, 2003, Allos and N-Gene signed a settlement agreement, under which Allos surrendered all rights and licenses to the intellectual property surrounding BGP-15.
Additional information available to subscribers only: